DK0882024T3 - Forbindelser, som inhiberer retroviral protease - Google Patents

Forbindelser, som inhiberer retroviral protease

Info

Publication number
DK0882024T3
DK0882024T3 DK96944941T DK96944941T DK0882024T3 DK 0882024 T3 DK0882024 T3 DK 0882024T3 DK 96944941 T DK96944941 T DK 96944941T DK 96944941 T DK96944941 T DK 96944941T DK 0882024 T3 DK0882024 T3 DK 0882024T3
Authority
DK
Denmark
Prior art keywords
compounds
retroviral protease
inhibit retroviral
inhibit
protease
Prior art date
Application number
DK96944941T
Other languages
Danish (da)
English (en)
Inventor
Hing Leung Sham
Daniel W Norbeck
Xiaoqi Chen
David A Betebenner
Dale J Kempf
Thomas R Herrin
Gondi N Kumar
Stephen L Condon
Arthur J Cooper
Daniel A Dickman
Steven M Hannick
Lawrence Kolaczkowski
Patricia A Oliver
Daniel J Plata
Peter J Stengel
Eric J Stoner
Jieh-Heh J Tien
Jih-Hua Liu
Ketan M Patel
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27075785&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK0882024(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Abbott Lab filed Critical Abbott Lab
Application granted granted Critical
Publication of DK0882024T3 publication Critical patent/DK0882024T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C07D207/263—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms
    • C07D207/27—2-Pyrrolidones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms with substituted hydrocarbon radicals directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses
    • A61P31/22—Antivirals for DNA viruses for herpes viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/18—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D207/22—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/24—Oxygen or sulfur atoms
    • C07D207/26—2-Pyrrolidones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • C07D207/408—Radicals containing only hydrogen and carbon atoms attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D223/00—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom
    • C07D223/02—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D223/06—Heterocyclic compounds containing seven-membered rings having one nitrogen atom as the only ring hetero atom not condensed with other rings with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D223/08—Oxygen atoms
    • C07D223/10—Oxygen atoms attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/32—One oxygen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/30—Oxygen or sulfur atoms
    • C07D233/42—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/10—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
    • C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/14—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D241/18—Oxygen or sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D253/00—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00
    • C07D253/02—Heterocyclic compounds containing six-membered rings having three nitrogen atoms as the only ring hetero atoms, not provided for by group C07D251/00 not condensed with other rings
    • C07D253/06—1,2,4-Triazines
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/18—Oxygen atoms
    • C07D263/20—Oxygen atoms attached in position 2
    • C07D263/22—Oxygen atoms attached in position 2 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/18—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D307/20—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biotechnology (AREA)
  • AIDS & HIV (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
DK96944941T 1995-12-13 1996-12-06 Forbindelser, som inhiberer retroviral protease DK0882024T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US57222695A 1995-12-13 1995-12-13
US08/753,201 US5914332A (en) 1995-12-13 1996-11-21 Retroviral protease inhibiting compounds
PCT/US1996/020440 WO1997021685A1 (en) 1995-12-13 1996-12-06 Retroviral protease inhibiting compounds

Publications (1)

Publication Number Publication Date
DK0882024T3 true DK0882024T3 (da) 2002-05-21

Family

ID=27075785

Family Applications (1)

Application Number Title Priority Date Filing Date
DK96944941T DK0882024T3 (da) 1995-12-13 1996-12-06 Forbindelser, som inhiberer retroviral protease

Country Status (20)

Country Link
US (6) US5914332A (cs)
EP (2) EP1170289A3 (cs)
JP (4) JP3170292B2 (cs)
KR (2) KR100404993B1 (cs)
CN (1) CN1207288C (cs)
AR (2) AR005053A1 (cs)
AT (1) ATE212986T1 (cs)
AU (1) AU725369C (cs)
CA (3) CA2238978C (cs)
CO (1) CO5070655A1 (cs)
CZ (5) CZ300131B6 (cs)
DE (1) DE69619140T2 (cs)
DK (1) DK0882024T3 (cs)
ES (1) ES2173341T3 (cs)
HK (1) HK1045303A1 (cs)
HU (2) HU222731B1 (cs)
IL (6) IL156237A (cs)
NZ (4) NZ326132A (cs)
PT (1) PT882024E (cs)
WO (1) WO1997021685A1 (cs)

Families Citing this family (121)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5914332A (en) 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US6232333B1 (en) 1996-11-21 2001-05-15 Abbott Laboratories Pharmaceutical composition
ZA9710071B (en) * 1996-11-21 1998-05-25 Abbott Lab Pharmaceutical composition.
WO1999066936A1 (en) * 1998-06-24 1999-12-29 Emory University Use of 3'-azido-2',3'-dideoxyuridine in combination with further anti-hiv drugs for the manufacture of a medicament for the treatment of hiv
DE60027131D1 (de) 1999-01-06 2006-05-18 Us Gov Health & Human Serv Inhibitoren für asparagin-proteasen
US7141593B1 (en) * 1999-06-04 2006-11-28 Abbott Laboratories Pharmaceutical formulations
CN101361723B (zh) * 1999-06-04 2013-11-06 Abbvie公司 改进的药物制剂
ATE329579T1 (de) * 1999-11-12 2006-07-15 Abbott Lab Feste dispersion mit ritonavir, fenofibrat oder griseofulvin
US7364752B1 (en) * 1999-11-12 2008-04-29 Abbott Laboratories Solid dispersion pharamaceutical formulations
NZ519724A (en) * 2000-01-19 2004-07-30 Abbott Lab Chad 0377 Ap6D 2 A combination solubilised HIV protease inhibiting compound, a medium and or long clain fatty acid and an alcohol that has improved solubility properties
US6608198B2 (en) * 2000-03-30 2003-08-19 Abbott Laboratories Crystalline pharmaceutical
MY128296A (en) * 2000-03-30 2007-01-31 Abbott Lab Crystalline pharmaceutical
EP1267879A2 (en) 2000-03-30 2003-01-02 Bristol-Myers Squibb Company Sustained release beadlets containing stavudine
DE10026698A1 (de) * 2000-05-30 2001-12-06 Basf Ag Selbstemulgierende Wirkstoffformulierung und Verwendung dieser Formulierung
US6372905B1 (en) 2000-08-31 2002-04-16 Abbott Laboratories Processes and intermediates for preparing retroviral protease inhibitors
KR100806533B1 (ko) * 2000-08-31 2008-02-25 아보트 러보러터리즈 레트로바이러스성 프로테아제 억제제를 제조하기 위한방법 및 중간체
US6911214B2 (en) 2000-09-05 2005-06-28 Abbott Laboratories Flavoring systems for pharmaceutical compositions and methods of making such compositions
EP1387684A1 (en) * 2001-05-01 2004-02-11 Abbott Laboratories Compositions comprising lopinavir and methods for enhancing the bioavailability of pharmaceutical agents
US20030138483A1 (en) * 2001-05-25 2003-07-24 Sergio Petriconi Soft elastic capsules and compositions thereof
US7838046B2 (en) * 2001-09-26 2010-11-23 Tampa Bay Research Institute Plant extracts and uses thereof
US6866875B2 (en) * 2001-09-26 2005-03-15 Tampa Bay Research Institute Pine cone extracts and uses thereof
US20030180279A1 (en) * 2002-03-19 2003-09-25 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
US20040197321A1 (en) * 2002-03-19 2004-10-07 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
US20070010489A1 (en) * 2002-04-26 2007-01-11 Arimilli Murty N Cellular accumulation of phosphonate analogs of hiv protease inhibitor compounds
US20050239054A1 (en) * 2002-04-26 2005-10-27 Arimilli Murty N Method and compositions for identifying anti-HIV therapeutic compounds
US7205413B2 (en) * 2002-05-03 2007-04-17 Transform Pharmaceuticals, Inc. Solvates and polymorphs of ritonavir and methods of making and using the same
ITMI20021168A1 (it) * 2002-05-30 2003-12-01 Clariant Lsm Italia Spa Procedimento per la preparazione dell'acido (s)-tetraidro-a-(1-metiletil)-2-osso-1(2h)-piridinacetico
US7470724B2 (en) * 2003-04-25 2008-12-30 Gilead Sciences, Inc. Phosphonate compounds having immuno-modulatory activity
US20050261237A1 (en) * 2003-04-25 2005-11-24 Boojamra Constantine G Nucleoside phosphonate analogs
WO2004096286A2 (en) 2003-04-25 2004-11-11 Gilead Sciences, Inc. Antiviral phosphonate analogs
CN101410120A (zh) * 2003-04-25 2009-04-15 吉里德科学公司 抗炎的膦酸酯化合物
US7432261B2 (en) * 2003-04-25 2008-10-07 Gilead Sciences, Inc. Anti-inflammatory phosphonate compounds
US7452901B2 (en) * 2003-04-25 2008-11-18 Gilead Sciences, Inc. Anti-cancer phosphonate analogs
WO2005002626A2 (en) * 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
US7427636B2 (en) * 2003-04-25 2008-09-23 Gilead Sciences, Inc. Inosine monophosphate dehydrogenase inhibitory phosphonate compounds
US7407965B2 (en) * 2003-04-25 2008-08-05 Gilead Sciences, Inc. Phosphonate analogs for treating metabolic diseases
WO2004096285A2 (en) * 2003-04-25 2004-11-11 Gilead Sciences, Inc. Anti-infective phosphonate conjugates
US20090247488A1 (en) * 2003-04-25 2009-10-01 Carina Cannizzaro Anti-inflammatory phosphonate compounds
EP1620109A2 (en) * 2003-04-25 2006-02-01 Gilead Sciences, Inc. Kinase inhibitor phosphonate conjugates
US20060148865A1 (en) * 2003-06-27 2006-07-06 Martin Michael T Preparation of chemical compounds
US20050048112A1 (en) 2003-08-28 2005-03-03 Jorg Breitenbach Solid pharmaceutical dosage form
US8377952B2 (en) 2003-08-28 2013-02-19 Abbott Laboratories Solid pharmaceutical dosage formulation
US8025899B2 (en) 2003-08-28 2011-09-27 Abbott Laboratories Solid pharmaceutical dosage form
WO2005044279A1 (en) * 2003-10-24 2005-05-19 Gilead Sciences, Inc. Purine nucleoside phosphonate conjugates
WO2005042772A1 (en) * 2003-10-24 2005-05-12 Gilead Sciences, Inc. Methods and compositions for identifying therapeutic compounds
US7432273B2 (en) * 2003-10-24 2008-10-07 Gilead Sciences, Inc. Phosphonate analogs of antimetabolites
US7834043B2 (en) * 2003-12-11 2010-11-16 Abbott Laboratories HIV protease inhibiting compounds
CA2549228C (en) * 2003-12-11 2013-03-19 Abbott Laboratories Hiv protease inhibiting compounds
ES2378669T3 (es) * 2003-12-11 2012-04-16 Abbott Laboratories Compuestos inhibidores de proteasa de VIH
US20050131042A1 (en) * 2003-12-11 2005-06-16 Flentge Charles A. HIV protease inhibiting compounds
US8193227B2 (en) 2003-12-11 2012-06-05 Abbott Laboratories HIV protease inhibiting compounds
US20050131017A1 (en) 2003-12-11 2005-06-16 Degoey David A. HIV protease inhibiting compounds
US20070281907A1 (en) * 2003-12-22 2007-12-06 Watkins William J Kinase Inhibitor Phosphonate Conjugates
US20080287471A1 (en) * 2003-12-22 2008-11-20 Maria Fardis 4'-Substituted Carbovir And Abacavir-Derivatives As Well As Related Compounds With Hiv And Hcv Antiviral Activity
US20050153990A1 (en) * 2003-12-22 2005-07-14 Watkins William J. Phosphonate substituted kinase inhibitors
UA85567C2 (en) 2003-12-23 2009-02-10 Тиботек Фармасьютикелз Лтд. Process for the preparation of (3r,3as,6ar)-hexahydrofuro [2,3-b] furan-3-yl (1s,2r)-3-[[(4-aminophenyl) sulfonyl] (isobutyl) amino]-1-benzyl-2-hydroxypropylcarbamate
US20050142124A1 (en) 2003-12-31 2005-06-30 Kaiser Jon D. Nutrient compositions and methods for enhanced effectiveness of the immune system
BRPI0401742B8 (pt) 2004-05-13 2021-05-25 Cristalia Produtos Quim Farmaceuticos Ltda composto análogo do ritonavir útil como inibidor de protease retroviral, preparação do composto análogo do ritonavir e composição farmacêutica do composto análogo do ritonavir
AU2005270124B2 (en) * 2004-07-06 2011-09-08 Abbvie Inc. Prodrugs of HIV protease inhibitors
ES2363160T3 (es) 2004-07-27 2011-07-22 Gilead Sciences, Inc. Conjugados de fosfonato nucelosidico como agentes anti-vih.
US20090047347A1 (en) * 2005-07-29 2009-02-19 Aegis Therapeutics, Inc. Compositions for Drug Administration
US20060046969A1 (en) * 2004-08-25 2006-03-02 Aegis Therapeutics Llc Antibacterial compositions for drug administration
US20140162965A1 (en) 2004-08-25 2014-06-12 Aegis Therapeutics, Inc. Compositions for oral drug administration
EP2457580A1 (en) * 2004-08-25 2012-05-30 The UAB Research Foundation Absorption enhancers for drug administration
US9895444B2 (en) 2004-08-25 2018-02-20 Aegis Therapeutics, Llc Compositions for drug administration
US20060046962A1 (en) 2004-08-25 2006-03-02 Aegis Therapeutics Llc Absorption enhancers for drug administration
US8268791B2 (en) * 2004-08-25 2012-09-18 Aegis Therapeutics, Llc. Alkylglycoside compositions for drug administration
WO2006100552A1 (en) * 2005-02-28 2006-09-28 Ranbaxy Laboratories Limited Processes for the preparation of lopinavir and its intermediate - (s)-tetrahydro-alpha-(1-methylethyl)-2-oxo-1(2h)-pyrimidineacetic acid
WO2006090264A1 (en) * 2005-02-28 2006-08-31 Ranbaxy Laboratories Limited A process for the synthesis of 2-amino-5-protected amino-3-hydroxy-1, 6-diphenylhexane or a salt thereof - an intermediate for antiviral drugs
CN101088991B (zh) * 2006-06-12 2013-05-22 浙江普洛医药科技有限公司 (s)-2-(2-羰基-四氢嘧啶-1(2h)-基)-3-甲基丁酸的制备方法
US8226949B2 (en) 2006-06-23 2012-07-24 Aegis Therapeutics Llc Stabilizing alkylglycoside compositions and methods thereof
US20100173921A1 (en) * 2006-08-10 2010-07-08 Cipla Limited Antiretroviral Solid Oral Composition
EP2112925A4 (en) * 2006-11-15 2013-01-09 Abbott Lab SOLID PHARMACEUTICAL DOSAGE FORMULATIONS
MX2009009850A (es) 2007-03-12 2009-09-24 Nektar Therapeutics Conjugados de inhibidor de oligomero-proteasa.
FR2914920B1 (fr) * 2007-04-11 2011-09-09 Clariant Specialty Fine Chem F Procede de deacetalisation d'alpha-aminoacetals.
AU2008270630B2 (en) * 2007-06-29 2014-01-16 Gilead Sciences, Inc. Therapeutic compositions and the use thereof
MX2009013828A (es) * 2007-06-29 2010-03-10 Gilead Sciences Inc Composiciones terapeuticas y su uso.
WO2009004653A2 (en) * 2007-07-04 2009-01-08 Matrix Laboratories Limited Process for preparing an amorphous form of (2s,3s,5s)-2-(2,6- dimethylphenoxyacetyl)-amino-3-hydroxy-5-(2-(1-tetrahydropyrimid-2-only)-3-methylbutanoyl)-amino-1,6-diphenyl hexane and product thereof
EP2188265A1 (en) * 2007-08-07 2010-05-26 Ranbaxy Laboratories Limited Process for preparation of amorphous lopinavir
EP3272337A3 (en) * 2008-02-28 2018-02-14 AbbVie Inc. Tablets
US9095620B2 (en) 2008-03-12 2015-08-04 Nektar Therapeutics Reagents
US20090258865A1 (en) 2008-03-28 2009-10-15 Hale Biopharma Ventures, Llc Administration of benzodiazepine compositions
DK2307435T3 (da) 2008-07-08 2012-09-10 Gilead Sciences Inc Salte af HIV-inhibitorforbindelser
US20100021505A1 (en) * 2008-07-28 2010-01-28 Tibor Sipos Composition and method to prevent or reduce diarrhea and steatorrhea in HIV patients
US20100137235A1 (en) * 2008-10-15 2010-06-03 Mutual Pharmaceutical Company, Inc. Methods for Concomitant Administration of Colchicine and Macrolide Antibiotics
US8440631B2 (en) 2008-12-22 2013-05-14 Aegis Therapeutics, Llc Compositions for drug administration
US7820681B1 (en) * 2009-01-14 2010-10-26 Mutual Pharmaceutical Company, Inc. Methods for concomitant administration of colchicine and a second active agent
ES2459301T3 (es) 2009-02-06 2014-05-08 Hetero Research Foundation Nuevos polimorfos de lopinavir
JP2012530069A (ja) 2009-06-12 2012-11-29 ネクター セラピューティックス プロテアーゼ阻害剤、水溶性非ペプチドオリゴマーおよび親油性部分を含む共有結合体
WO2011013110A1 (en) 2009-07-31 2011-02-03 Ranbaxy Laboratories Limited Unit dosage forms of hiv protease inhibitors
US20110034489A1 (en) * 2009-07-31 2011-02-10 Ranbaxy Laboratories Limited Solid dosage forms of hiv protease inhibitors
SG10201707183TA (en) 2010-01-27 2017-10-30 Viiv Healthcare Co Antiviral therapy
CN101967130B (zh) * 2010-07-02 2012-12-26 厦门市亨瑞生化有限公司 利托那韦中间体的合成方法
CN101967092A (zh) * 2010-07-02 2011-02-09 厦门市亨瑞生化有限公司 2,6-二甲基苯氧乙酸的合成方法
US9174944B1 (en) 2010-12-17 2015-11-03 Abbvie Inc. Crystalline lopinavir/surfactant adducts
CA2829186A1 (en) * 2011-03-07 2012-09-13 Bandi Parthasaradhi Reddy Amorphous form of lopinavir and ritonavir mixture
WO2012164575A2 (en) 2011-05-27 2012-12-06 Hetero Research Foundation Amorphous ritonavir co-precipitated
PL3415139T3 (pl) 2011-06-14 2022-07-11 Neurelis, Inc. Podawanie benzodiazepiny
US9040082B2 (en) 2011-06-24 2015-05-26 K-Pax Pharmaceuticals, Inc. Compositions and methods for treatment of chronic fatigue
EP2785332A1 (en) 2011-11-28 2014-10-08 Ranbaxy Laboratories Limited A process for the preparation of solid dispersion of lopinavir and ritonavir
MX2014013326A (es) 2012-05-03 2015-08-10 Cipla Ltd Composición antirretroviral.
US9227990B2 (en) 2012-10-29 2016-01-05 Cipla Limited Antiviral phosphonate analogues and process for preparation thereof
MY182716A (en) 2013-01-30 2021-02-03 Sumitomo Chemical Co Method for controlling arthropod pest
CN103936679B (zh) * 2014-03-03 2016-05-11 厦门市亨瑞生化有限公司 一种2s—(1—四氢嘧啶—2—酮)—3—甲基丁酸的制备方法
US9738664B2 (en) 2014-10-29 2017-08-22 Wisconsin Alumni Research Foundation Boronic acid inhibitors of HIV protease
RU2573991C1 (ru) * 2015-04-29 2016-01-27 Закрытое акционерное общество "ПЕПТЕК" Способ получения n-ацетилглюкозаминил-n-ацетилмурамил-l-аланил-d-глутаминовой кислоты
WO2017059113A1 (en) * 2015-09-29 2017-04-06 Duke University Compositions and methods for identifying and treating dystonia disorders
UA118192C2 (uk) * 2015-10-22 2018-12-10 Юрій Захарович Толчеєв Противірусна фармацевтична композиція
EP3939570A1 (en) * 2016-02-18 2022-01-19 Immune Therapeutics, Inc. Naltrexone for treating or preventing autoimmune and inflammatory diseases
CN106117148B (zh) * 2016-06-17 2019-04-12 厦门市蔚嘉化学科技有限公司 一种洛匹那韦的制备和纯化工艺
CN106380412A (zh) * 2016-08-31 2017-02-08 中国科学院新疆生态与地理研究所 一种合成利托那韦中间体的方法
CN111065385A (zh) 2017-06-22 2020-04-24 希普拉有限公司 癌症的治疗方法
SI3661937T1 (sl) 2017-08-01 2021-11-30 Gilead Sciences, Inc. Kristalinične oblike etil((S)-((((2R,5R)-5-(6-amino-9H-purin-9-IL)-4- fluoro-2,5-dihidrofuran-2-IL)oksi)metil)(fenoksi)fosforil)-L-alaninata (GS-9131) za zdravljenje virusnih okužb
CN107602454B (zh) * 2017-09-19 2020-12-01 佛山科学技术学院 磺酰胺类化合物及其制备方法和用途
JP2020031151A (ja) * 2018-08-23 2020-02-27 キオクシア株式会社 半導体記憶装置およびその製造方法
KR102783030B1 (ko) * 2019-02-01 2025-03-18 재단법인 경기도경제과학진흥원 중동호흡기증후군 치료 또는 예방용 약학 조성물
US20230218644A1 (en) 2020-04-16 2023-07-13 Som Innovation Biotech, S.A. Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus
CN111393329A (zh) * 2020-04-16 2020-07-10 安徽一帆香料有限公司 一种利托那韦和洛匹那韦中间体的制备方法
CN112574027A (zh) * 2020-12-17 2021-03-30 盐城迪赛诺制药有限公司 一种2,6-二甲基苯氧基乙酸的生产工艺
CN118488831A (zh) 2021-12-23 2024-08-13 苏宾特罗有限公司 包含油酸的新抗病毒组合物
CN115784936B (zh) * 2022-12-19 2023-12-26 启东东岳药业有限公司 一种利托那韦关键中间体bdh的制备方法

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3751262A (en) * 1970-06-30 1973-08-07 Allied Chem Ruminant feed supplement
GB1539817A (en) * 1976-10-22 1979-02-07 Ucb Sa N-substituted lactams
DE2960194D1 (en) * 1978-05-08 1981-04-16 Ucb Sa Lactam-n-acetic acids, their amides, process for their preparation and therapeutic compositions containing them
JPS54157586A (en) * 1978-05-30 1979-12-12 Toyama Chem Co Ltd Penicillin and cephalosporin
US5142056A (en) * 1989-05-23 1992-08-25 Abbott Laboratories Retroviral protease inhibiting compounds
US4448816A (en) 1983-08-04 1984-05-15 The Upjohn Company Compounds, compositions and process
US4885292A (en) 1986-02-03 1989-12-05 E. R. Squibb & Sons, Inc. N-heterocyclic alcohol renin inhibitors
US5472946A (en) * 1988-04-08 1995-12-05 Peck; James V. Transdermal penetration enhancers
IL90218A0 (en) * 1988-05-13 1989-12-15 Abbott Lab Retroviral protease inhibitors
US5164388A (en) 1988-10-19 1992-11-17 Abbott Laboratories Heterocyclic peptide renin inhibitors
IL92011A0 (en) * 1988-10-19 1990-07-12 Abbott Lab Heterocyclic peptide renin inhibitors
US5354866A (en) 1989-05-23 1994-10-11 Abbott Laboratories Retroviral protease inhibiting compounds
US5696270A (en) 1989-05-23 1997-12-09 Abbott Laboratories Intermediate for making retroviral protease inhibiting compounds
EP0428849A3 (en) * 1989-09-28 1991-07-31 Hoechst Aktiengesellschaft Retroviral protease inhibitors
GB8927913D0 (en) 1989-12-11 1990-02-14 Hoffmann La Roche Amino acid derivatives
ES2059295T3 (es) 1990-11-19 1998-06-01 Monsanto Co Inhibidores de las proteasas retrovirales.
IE913840A1 (en) * 1990-11-20 1992-05-20 Abbott Lab Retroviral protease inhibiting compounds
CA2056911C (en) 1990-12-11 1998-09-22 Yuuichi Nagano Hiv protease inhibitors
GB9111902D0 (en) 1991-06-03 1991-07-24 Glaxo Group Ltd Chemical compounds
US5643878A (en) 1991-09-12 1997-07-01 Ciba-Geigy Corporation 5-amino-4-hydroxyhexanoic acid derivatives
EP0532466A3 (en) 1991-09-12 1993-06-16 Ciba-Geigy Ag Derivatives of 5-amino-4-hydroxy-hexanoic acid and their therapeutical use
HU221816B1 (hu) * 1991-10-11 2003-01-28 Bristol-Myers Squibb Pharma Company Gyűrűs karbonil vegyületek, és ezeket tartalmazó gyógyászati készítmények
US5413999A (en) 1991-11-08 1995-05-09 Merck & Co., Inc. HIV protease inhibitors useful for the treatment of AIDS
ATE116640T1 (de) 1992-03-13 1995-01-15 Bio Mega Boehringer Ingelheim Substituierte pipecoline-säurederivate als hiv- protease-hemmer.
DE4213659C2 (de) * 1992-04-25 1995-06-08 Koenig & Bauer Ag Kurzfarbwerk für eine Rotationsdruckmaschine
DK0641333T3 (da) 1992-05-20 1996-09-02 Monsanto Co Fremgangsmåde til fremstilling af mellemprodukter, som er anvendelige ved syntese af retrovirus- protease-inhibitorer
US5559256A (en) * 1992-07-20 1996-09-24 E. R. Squibb & Sons, Inc. Aminediol protease inhibitors
IS2334B (is) 1992-09-08 2008-02-15 Vertex Pharmaceuticals Inc., (A Massachusetts Corporation) Aspartyl próteasi hemjari af nýjum flokki súlfonamíða
AU4859593A (en) 1992-09-15 1994-04-12 Southern Research Institute 5,5-disubstituted hydantoins
US5484926A (en) 1993-10-07 1996-01-16 Agouron Pharmaceuticals, Inc. HIV protease inhibitors
ATE143262T1 (de) 1992-12-29 1996-10-15 Abbott Lab Inhibitoren der retroviralen protease
DE4318550A1 (de) * 1993-06-04 1994-12-08 Boehringer Mannheim Gmbh Aryliden-4-oxo-2-thioxo-3- thiazolidincarbonsäuren, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5750648A (en) 1993-08-20 1998-05-12 G.D. Searle & Co. Retroviral protease inhibitors and combinations thereof
IL110752A (en) * 1993-09-13 2000-07-26 Abbott Lab Liquid semi-solid or solid pharmaceutical composition for an HIV protease inhibitor
US5468733A (en) * 1993-09-30 1995-11-21 Merck & Co., Inc. Inhibitors of farnesyl-protein transferase
US5559158A (en) * 1993-10-01 1996-09-24 Abbott Laboratories Pharmaceutical composition
US5770573A (en) 1993-12-06 1998-06-23 Cytel Corporation CS-1 peptidomimetics, compositions and methods of using the same
IL111991A (en) * 1994-01-28 2000-07-26 Abbott Lab Liquid pharmaceutical composition of HIV protease inhibitors in organic solvent
JPH08151364A (ja) 1994-02-18 1996-06-11 Nissan Chem Ind Ltd 含窒素環状化合物および除草剤
IL129871A (en) 1994-05-06 2003-11-23 Pharmacia & Upjohn Inc Process for preparing 4-phenyl-substituted octanoyl-oxazolidin-2-one intermediates that are useful for preparing pyran-2-ones useful for treating retroviral infections
AU3150395A (en) * 1994-08-09 1996-03-07 Abbott Laboratories Retroviral protease inhibiting 1,2,4-triazacycloheptanes
US6037157A (en) 1995-06-29 2000-03-14 Abbott Laboratories Method for improving pharmacokinetics
WO1997017180A1 (en) 1995-11-07 1997-05-15 Lonza Inc. Halohydantoin forms and method by melt extrusion
US5914332A (en) * 1995-12-13 1999-06-22 Abbott Laboratories Retroviral protease inhibiting compounds
US5883252A (en) * 1996-01-26 1999-03-16 Vertex Pharmaceuticals Incorporated Aspartyl protease inhibitors
FR2773994B1 (fr) 1998-01-23 2002-10-11 Univ Nice Sophia Antipolis Prodrogues issues d'anti-proteases inhibitrices du virus de l'immunodeficience humaine (vih) pour l'amelioration de leur biodisponibilite, de leur tropisme vers et/ou de leur delivrance dans le systeme nerveux central
DE60027131D1 (de) * 1999-01-06 2006-05-18 Us Gov Health & Human Serv Inhibitoren für asparagin-proteasen

Also Published As

Publication number Publication date
JP2013047266A (ja) 2013-03-07
US5914332A (en) 1999-06-22
JP5597689B2 (ja) 2014-10-01
AR005053A1 (es) 1999-04-07
IL156236A0 (en) 2004-01-04
AR025352A1 (es) 2002-11-20
NZ326132A (en) 1999-11-29
CA2238978A1 (en) 1997-06-19
CN1207288C (zh) 2005-06-22
IL156237A0 (en) 2004-01-04
HUP9901079A3 (en) 2000-08-28
EP0882024B1 (en) 2002-02-06
HU223782B1 (hu) 2005-01-28
IL136661A0 (en) 2001-06-14
NZ338003A (en) 2005-08-26
NZ510329A (en) 2004-02-27
CZ293650B6 (cs) 2004-06-16
CA2285119A1 (en) 1997-06-19
IL156237A (en) 2005-05-17
US20030100755A1 (en) 2003-05-29
US6284767B1 (en) 2001-09-04
KR19990072195A (ko) 1999-09-27
US7968707B2 (en) 2011-06-28
CA2285119C (en) 2005-09-20
JP5264160B2 (ja) 2013-08-14
US20080139811A1 (en) 2008-06-12
ATE212986T1 (de) 2002-02-15
HUP9901079A2 (hu) 1999-09-28
IL156236A (en) 2006-10-31
CZ176298A3 (cs) 1998-11-11
PT882024E (pt) 2002-07-31
US6313296B1 (en) 2001-11-06
KR100418316B1 (ko) 2004-02-11
JP4181291B2 (ja) 2008-11-12
HK1016585A1 (en) 1999-11-05
EP0882024A1 (en) 1998-12-09
CA2509505A1 (en) 1997-06-19
CZ300127B6 (cs) 2009-02-18
HUP0003305A3 (en) 2000-12-28
JP2001058979A (ja) 2001-03-06
CO5070655A1 (es) 2001-08-28
EP1170289A3 (en) 2002-11-13
AU725369B2 (en) 2000-10-12
DE69619140D1 (de) 2002-03-21
CZ294246B6 (cs) 2004-11-10
HU222731B1 (hu) 2003-09-29
EP1170289A2 (en) 2002-01-09
CZ296915B6 (cs) 2006-07-12
US7279582B2 (en) 2007-10-09
JP2000502085A (ja) 2000-02-22
JP2008115189A (ja) 2008-05-22
ES2173341T3 (es) 2002-10-16
CZ300131B6 (cs) 2009-02-18
IL173966A (en) 2012-02-29
NZ510328A (en) 2005-01-28
WO1997021685A1 (en) 1997-06-19
AU725369C (en) 2003-04-10
IL124607A0 (en) 1998-12-06
KR100404993B1 (ko) 2004-06-04
JP3170292B2 (ja) 2001-05-28
IL173966A0 (en) 2006-07-05
CA2238978C (en) 2001-05-15
US6472529B2 (en) 2002-10-29
CN1208405A (zh) 1999-02-17
MX9804734A (es) 1998-10-31
AU1342297A (en) 1997-07-03
HK1045303A1 (en) 2002-11-22
DE69619140T2 (de) 2002-10-31
US20020004503A1 (en) 2002-01-10

Similar Documents

Publication Publication Date Title
DK0882024T3 (da) Forbindelser, som inhiberer retroviral protease
FI931278L (fi) Polymerer, som innehaoller sulfogrupper
FI922222A7 (fi) Kopplingsanordning, som foermaor laosa spinalosteosyntesfaestanordningar
FI925615L (fi) Stabiliserade farmaceutiska kompositioner, som innehaoller en HMG-CoA-reduktas-inhibitorfoerening
FI913215L (fi) Additionspolymeriseringskatalysator, som aktiveras medelst oxidering.
FI931367L (fi) Tvaettmedelskompositioner, som innehaoller polyhydroxifettsyraamider ochen skumfoerstaerkare
FI923281L (fi) Foerbaettrade desinfektionsloesningar, som innehaoller vaeteperoxid
FI932527L (fi) Anvaendning av polypropylenglykol saosom tillsatsaemne, som reducerar krympningens storlek i dispersionspulversammansaettningar avsedda foer byggmaterialer
FI931336L (fi) Laekemedel som innehaoller polyhydroximetylenderivat, foerfarande foer deras framstaellning och bruk
FI941307A0 (fi) Tjulvalarm, som aktiveras av foeremaolets, som skall skyddas, roerelse
FI932654L (fi) Hydroxamsyraderivat, som hindrar lipoxigenas
FI932873A7 (fi) D-homo-(16-en)-11b-aryl-4-estrener, foerfarande foer deras framstaellningoch deras anvaendning som laekemedel
FI920080A0 (fi) Kulfaongare, som uppstannar kulor.
FI933507A0 (fi) Bicyklopolyazamakrocyklofosfonsyror, komplex och konjugat daerav att anvaendas som kontrastmedel och foerfarande foer deras framstaellning
FI930217A7 (fi) Hoegt tvaerbundna, smaott avdunstande organiska foereningar innehaollande ytbelaeggningskompositioner som omfattar polyuretandispersioner
FI934468L (fi) Bensenborsyraderivat, foerfarande foer deras framstaellning och deras anvaendning som sytes mellanprodukter
DK0770603T3 (da) Alkynylphenylaminosulfonylurinstoffer som herbicider
TR199600665A2 (tr) Asimetrik trifenilendioksazin bilesikleri.
FIU920599U0 (fi) Spanjolett som staeng, automatiskt
FI922997A0 (fi) Tuggummi som innehaoller verksamma aemnen.
FI921234A0 (fi) Saekerhetsanordning som avstaenger oljekaellans produktionsledning.
MX9204259A (es) Compuestos inhibidores de proteasa retroviral.
FI963725A0 (fi) Bastuugn som vaermar vatten
FI960675A0 (fi) Kortslutningsskydd foer en som belastningskoppling fungerande FET-transistor
FI961508A0 (fi) Ledningskanal som ocksao fungerar som foensterbraede